FDA Determines CHEWTADZY Tablets Not Withdrawn for Safety or Effectiveness
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA determined that CHEWTADZY chewable tablets, available in 5 mg, 10 mg, and 20 mg dosages, were not withdrawn from the market due to safety or effectiveness concerns. This finding allows the FDA to approve generic versions of these tablets through abbreviated new drug applications (ANDAs), provided they meet all regulatory requirements. This decision affects generic drug manufacturers seeking to produce their versions of this medication.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA determined CHEWTADZY tablets were not withdrawn for safety/effectiveness.
- Approval of generic versions through ANDAs is possible.
- Decision impacts generic drug manufacturers.
Obligations
What this law requires
Generic drug manufacturers must submit abbreviated new drug applications (ANDAs) for CHEWTADZY (tadalafil) chewable tablets to obtain FDA approval.
ANDA applicants must demonstrate that their generic product has the same active ingredient(s), dosage form, route of administration, strength, and conditions of use as the listed drug.
ANDA applicants must prove that their generic drug product is bioequivalent to CHEWTADZY (tadalafil) chewable tablets.
FDA must maintain a list of all approved drugs, including CHEWTADZY (tadalafil) chewable tablets, in the 'Approved Drug Products With Therapeutic Equivalence Evaluations' known as the Orange Book.
FDA must approve ANDAs that refer to CHEWTADZY (tadalafil) chewable tablets as long as all other legal and regulatory requirements are met.